Bio Substitution Plan Would Put Germany On ‘Wrong Track’
Plans for substituting biological drugs at pharmacy level that have been passed by Germany’s lower house of parliament threaten to undo the good work done to date in winning trust in biosimilars, local industry association Pro Biosimilars fears.
You may also be interested in...
Grouping together biosimilar adalimumabs and etanercepts with patented biologics in the same reference-price group in Germany threatens to remove biosimilars’ market advantage and weaken competition, local industry fears.
A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.
A consultation exercise has convinced Finland’s Fimea medicines agency that pharmacy-level substitution of biologic drugs is viable. But several safeguards and conditions it is proposing could limit the effects of such substitution on uptake.